Phase II study of dasatinib (BMS-354825) in patients with metastatic adenocarcinoma of the pancreas.

ABSTRACT:

Background

Src, EphA2, and platelet-derived growth factor receptors α and β are dysregulated in pancreatic ductal adenocarcinoma (PDAC).

Methods

Dasatinib is an oral multitarget tyrosine kinase inhibitor that targets BCR-ABL, c-Src, c-KIT, platelet-derived growth factor receptor β, and EphA2. We conducted a phase II, single-arm study of dasatinib as first-line therapy in patients with metastatic PDAC.

Methods

Dasatinib (100 mg twice a day, later reduced to 70 mg twice a day because of toxicities) was orally administered continuously on a 28-day cycle. The primary endpoint was overall survival (OS). Response was measured using the Response Evaluation Criteria in Solid Tumors. Circulating tumor cells (CTCs) were also collected.

Results

Fifty-one patients enrolled

SUBMITTER: Chee CE 

PROVIDER: S-EPMC3805150 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature